N-端脑钠肽前体测定在高血压疾病中的应用研究  

Application on NT-proBNP in Patients with Essential Hypertension

作　　者：李小侠[1] 詹颉[1] 张华[1] 党小军[1] 赵海[1] 奚逢瑜[1] 李博[1] 

机构地区：[1]陕西省人民医院检验科

出　　处：《现代检验医学杂志》2016年第5期100-102,共3页Journal of Modern Laboratory Medicine

摘　　要：目的：探讨血清 N端脑钠肽前体（NT-proBNP）在高血压疾病的应用研究。方法选择152例高血压患者纳入研究，根据高血压病情发展分为高血压1级（30例），高血压2级（36例）和高血压3级（86例）。86例高血压3级患者根据有无并发糖尿病又分为单纯高血压组（40例）和高血压并发糖尿病组（46例），分别比较不同分级组的血清 NT-proBNP水平变化。结果高血压1级患者、2级患者和3级患者血清中 NT-proBNP水平分别为68±44，122±31和834±309 pg／ml。随着病情发展其血清水平逐渐升高（t＝2.455，3.561，P＜0.01），高血压3级患者中高血压并发糖尿病组和单纯高血压组血清中NT-proBNP分别为1178±664 pg／ml和599±411 pg／ml（t＝3.785，P＜0.01）。结论 NT-proBNP水平能客观反映高血压患者的病情程度，对临床治疗和病情监测有一定的指导意义。Objective To study the N terminal pro brain natriuretic peptide （NT-proBNP）in serum of hypertension patients. Methods 152 patients with hypertension were included in this study.According to the different degree and development of hypertension,152 patients were divided into three different grade group of hypertension：first grade of hypertension group （30 patients）,second grade of hypertension group （36 patients）and third grade of hypertension group （86 patients）.And the 86 patients were divided into hypertension group （40 patients）and hypertension with diabetes group （46 patients）re-spectively,comparaed with the level of NT-proBNP in serum of different hypertension grade groups.Results The levels of the NT-proBNP in serum were 68±44,122±31 and 834±309 pg/ml of first grade of hypertension group,second grade of hypertension group and third grade of hypertension group,respectively.The level of the NT-proBNP was gradually increased with grade of hypertension （t=2.455,3.561,P〈0.01）.The level of the NT-proBNP （1 178±864 pg/ml）of hypertension with diabetes group was significantly higher than hypertension group （599±411 pg/ml）（t=3.785,P〈0.01）.Conclusion The level of NT-proBNP can obj ectively reflect the grade of the disease in patients with hypertension.it is a certain signifi-cance guiding for monitoring the clinical treatment of the disease.

关 键 词：脑钠肽 N-端脑钠肽前体 高血压 糖尿病 

分 类 号：R544.1[医药卫生—心血管疾病] R446.112[医药卫生—内科学]